Work

Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort

Year: 2015

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2015-ct324

Authors: Ursula A. Matulonis, Gerburg Wulf, William Barry, Michael Birrer, Shannon Westin, Tatum Spagnoletti, Katherine Bell-McGuinn, Elizabeth Obermayer, Christin Whalen, Carol Aghajanian, David Solit, Gordon Mills, Lewis Cantley, Eric Winer

Institutions: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Cornell University, Weill Cornell Medicine

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1661254177

Cites:

Cited by: 21

Related to: 10